Compare Canopy Growth Corp (CGC) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Canopy Growth Corp vs Novavax Inc — how do they compare? Canopy Growth Corp trades at $1.03 (market cap $421.10M), while Novavax Inc trades at $7.93 (market cap $1.31B). The key difference: Novavax Inc is far larger — about 3.1× Canopy Growth Corp's market cap, and Novavax Inc is trading nearer its 52-week high, Canopy Growth Corp nearer its low. Which is the better fit depends on your goals.
| CGC | NVAX | |
|---|---|---|
Market Cap | $421.10M | $1.31B |
Sector | Health | Health |
52-Week High | $1.92 | $11.19 |
52-Week Low | $0.86 | $6.22 |
Enterprise Value | $378.55M | $889.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Canopy Growth (CGC) trades at $1.025, up 7.66% with bullish technical signals. The company shows improving fundamentals with Q1 2027 revenue growth of 13% and narrowing losses. Recent acquisitions and cost-cutting initiatives support expansion in medical and European cannabis markets. The stock trades below book value (P/B 0.86) while maintaining a P/S ratio of 1.71.
CGC presents a high-risk turnaround opportunity with improving balance sheet metrics and positive revenue momentum. However, persistent negative earnings and cash flow challenges require careful monitoring. Analyst sentiment remains divided with 33% buy ratings, reflecting the speculative nature of cannabis sector investments amid ongoing regulatory uncertainty.
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Canopy Growth Corp
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
